Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

@article{Capdeville2002GlivecI,
  title={Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug},
  author={R. Capdeville and E. Buchdunger and J. Zimmermann and A. Matter},
  journal={Nature Reviews Drug Discovery},
  year={2002},
  volume={1},
  pages={493-502}
}
In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research. Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery programme was initiated with the aim of rationally developing targeted anticancer therapies. Here, we describe how this programme led… Expand

Figures, Tables, and Topics from this paper

Paper Mentions

Interventional Clinical Trial
Open-labeled, multicenter, phase I/II study of imatinib combined with ESHAP as salvage therapy in relapsed/refractory non-Hodgkin's lymphoma  
ConditionsLymphoma, Non-Hodgkin
InterventionDrug
Selective anticancer drugs
TLDR
With genomics and proteomics technologies poised to have an increasing impact, it seems a new era in anticancer therapy is beginning. Expand
Imatinib: a targeted clinical drug development.
TLDR
Preliminary results of a randomized study have demonstrated superior efficacy and safety of first-line imatinib therapy compared with a combination of interferon and cytarabine. Expand
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
TLDR
The discovery and continuing development of sorafenib is described, the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature. Expand
Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
  • G. Demetri
  • Medicine
  • The Journal of clinical investigation
  • 2007
TLDR
The study shows that structural reengineering of a kinase-inhibitory drug to improve tolerability while preserving efficacy is feasible and demonstrated with less cardiotoxicity of WBZ_4 compared with imatinib via the inhibition of JNK. Expand
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
TLDR
A highly potent and selective small-molecule inhibitor of Aurora kinases, VX-680, that blocks cell-cycle progression and induces apoptosis in a diverse range of human tumor types, leading to regression of leukemia, colon and pancreatic tumors at well-tolerated doses. Expand
Gastric cancer management: Kinases as a target therapy
TLDR
The mutational landscape of gastric cancer, the use of kinase inhibitors as targeted therapies in gastric tumours and the clinical trials underway for novel inhibitors are examined, highlighting successes, failures and future directions. Expand
Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells
TLDR
It is shown that imatinib inhibits PDGF phosphorylation not only in wt Kaposi sarcoma (KS) but also in multi drug resistant KS cells, which was associated with an increased apoptosis in wT cells and an increased autophagy in MDR‐KS cells. Expand
Selective Kinase Inhibitors in Cancer
TLDR
This article aims to show how medicinal chemistry is delivering a new generation of highly selective kinase inhibitors which are already delivering a step-change in benefit to cancer patients. Expand
The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.
TLDR
This review collates information from the journal and patent literature to provide a comprehensive reference source of the different synthetic methods used to prepare the active pharmaceutical ingredients (API's). Expand
A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma
TLDR
The therapeutic landscape of metastatic melanoma has recently moved from the dark ages to a period of renewed hope with two novel agents receiving regulatory approval and several agents currently in development that hold promise to further advance clinical outcomes for patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 104 REFERENCES
Pharmacology of imatinib (STI571).
TLDR
Imatinib has shown activity in vivo against PDGF-driven tumor models including glioblastoma, dermatofibrosarcoma protuberans and chronic myelomonocytic leukemia, and is also a potent inhibitor of the Kit receptor tyrosine kinase. Expand
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
TLDR
The results suggest that compounds that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity. Expand
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
Gastrointestinal stromal tumors are a group of mesenchymal neoplasms that arise from precursors of the connective-tissue cells of the gastrointestinal tract.1 They occur predominantly in middle-agedExpand
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.
TLDR
Overexpression of the Bcr/Abl protein mediated through gene amplification is associated with and probably determines resistance of human leukemic cells to STI571 in vitro. Expand
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
TLDR
It is found that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined and a strategy for identifying inhibitors of STI-571 resistance is suggested. Expand
Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives
Abstract Due to its relatively clear etiology, Chronic myelogenous leukemia (CML) represents an ideal disease target for a therapy using a selective inhibitor of the Bcr-Abl tyrosine protein kinase.Expand
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
TLDR
Impatinib at a dose of 400 mg twice daily is well tolerated during the first 8 weeks, side-effects diminish with continuing treatment, and it has significant activity in patients with advanced GISTs. Expand
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.
TLDR
Four tyrosine kinase inhibitors that have activity against KIT are currently being used in clinical trials, and one, STI571, has recently been approved by the United States Food and Drug Administration for treating patients with chronic myelogenous leukemia. Expand
Growth‐inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement
TLDR
The data indicate that STI571 might be a candidate compound for the pharmacological treatment of DP and demonstrate that the same compound may act in different ways, according to the specificity of the inhibited tyrosine kinase, namely, ABL or PDGFrβ. Expand
Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins.
TLDR
Data suggest that optimized pharmacological inhibitors of Kit activity may be a new class of compounds potentially useful in the treatment of SCLC. Expand
...
1
2
3
4
5
...